Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting (HNPCC)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Case Western Reserve University
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Vanderbilt University
Information provided by (Responsible Party):
Kaiser Permanente
ClinicalTrials.gov Identifier:
NCT01582841
First received: December 15, 2011
Last updated: August 11, 2014
Last verified: August 2014

December 15, 2011
August 11, 2014
February 2012
July 2015   (final data collection date for primary outcome measure)
Implementation effectiveness [ Time Frame: All patients will be followed up to 5 years. Most active participation and chart review will take place within one year of surgery. ] [ Designated as safety issue: No ]
The primary outcomes to assess implementation effectiveness are: number of patients who receive HNPCC screening test results; number of physicians who receive their patients HPNCC screening test results; completion of the educational session at three months of follow-up; and number of patients with MSI-H (microsatellite instability-high) test results who are contacted by medical genetics.
Implementation effectiveness [ Time Frame: All patients will be followed up to 5 years. Most active participation and chart review will take place within one year of surgery. ] [ Designated as safety issue: No ]
The primary outcomes to assess implementation effectiveness are: number of patients who receive HNPCC screening test results; number of physicians who receive their patients HPNCC screening test results; completion of the educational session at three months of follow-up; and number of patients with MSI-H test results who are contacted by medical genetics.
Complete list of historical versions of study NCT01582841 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting

The investigators research mobilizes the resources of an integrated health-delivery system with extensive electronic clinical data to implement and evaluate a new strategy to maximize screening of Colorectal Cancer (CRC) patients for Lynch Syndrome.

Screening tests for Hereditary Non-Polyposis Colorectal Cancer (HNPCC) [also called Lynch Syndrome], are among the few available validated genetic tests that have been recommended as an evidence-based practice that can save lives. However, more than half of patients who meet well-established and accepted screening criteria do not receive screening. This is a critical failure for patients and for the health-care delivery system because HNPCC mutation carriers are at exceptionally high risk for colorectal and other HNPCC-related cancers, and because clinical strategies can prevent future cancers, or provide early detection, for individuals affected with HNPCC and their relatives. HNPCC testing is also cost-effective compared to treating individuals with a diagnosis of colorectal cancer (CRC).

To address this shortfall in practice, our proposed research mobilizes the resources of an integrated health-delivery system with extensive electronic clinical data to implement and evaluate a new strategy to maximize screening of CRC patients for HPNCC. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working group recommended that all newly diagnosed CRC patients be screened for HPNCC, but was not able to recommend a best-strategy to accomplish this aim. Therefore, using the Practical Robust Implementation and Sustainability Model (PRISM), developed by one of our co-investigators, to guide the analyses, the investigators will:

Aim #1: Conduct a randomized controlled trial to determine the effectiveness of a universal laboratory test-based HNPCC screening program compared to the current practice of physician referral and self-referral.

Aim #2: Elucidate patient, provider, and system factors important to success of implementation.

Aim #3: (revised and approved during year 1): To create, refine, and disseminate an implementation guide for HNPCC screening by combining the results from Aims 1-2 and the perspectives from informant interviews of key staff at future diverse dissemination-implementation sites: Case Western Reserve University, Oregon Health & Sciences University, MD Anderson Cancer Center, Dana-Farber Cancer Institute, Kaiser Permanente Georgia, Kaiser Permanente Hawaii, and Safety Net West Clinics. Addition to Aim 3: We will contribute materials to the LSSN website for dissemination of implementation materials.

This study aims to evaluate implementation of a novel HNPCC screening program and assess, for all stakeholders, facilitators and barriers to program implementation and success. Results from this study will help achieve the Healthy People 2020 objective of reducing CRC mortality. It will add to the growing literature in the increasingly important area of translating research findings into real-world practice, a subject of the NIH Roadmap. Many of the findings will be useful in other clinical areas and will be broadly applicable to other health care organizations aiming to improve access to genetic tests for cancers.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Screening
  • Colon Cancer
  • Lynch Syndrome
Procedure: MSI screening test
All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
  • Experimental: MSI testing
    All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI following surgery. Those with MSI-H results will receive a genetic counseling informational call.
    Intervention: Procedure: MSI screening test
  • No Intervention: Usual care
    These patients will be treated as usual by their oncologist and medical team. These patients receive a follow up letter a year after randomization, alerting them to the availability of clinical Lynch Syndrome screening.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
1200
December 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. At least 18 years old
  2. Kaiser Permanente member
  3. Referral or scheduled colon surgery
  4. No known cognitive impairments (e.g., Alzheimer's Disease) that would impact the ability to be consented
  5. English speaker
  6. Diagnosis of colon cancer

Exclusion Criteria:

  1. Under the age of 18
  2. Known cognitive impairment
  3. Inability to speak/understand English
  4. On the research exclusion list
  5. Known Lynch syndrome
  6. No diagnosis of colon cancer
  7. In hospice
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01582841
1RO1CA140377-01A2
No
Kaiser Permanente
Kaiser Permanente
  • Case Western Reserve University
  • M.D. Anderson Cancer Center
  • Dana-Farber Cancer Institute
  • Vanderbilt University
Principal Investigator: Katrina AB Goddard, PhD Kaiser Permanente
Kaiser Permanente
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP